Ocular drops after late-stage trial data for wet AMD therapy
Source: SeekingAlpha
2026-02-17 08:25:08 ET
More on Ocular Therapeutix
- Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect
- Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix
- Ocular surges on report of Sanofi buyout bid
- Seeking Alpha’s Quant Rating on Ocular Therapeutix
Read the full article on Seeking Alpha
For further details see:
Ocular drops after late-stage trial data for wet AMD therapy
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-1.59% G/L:
$742.885 Last:
150,713 Volume:
$754.55 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
